Sanofi India Limited has informed the Exchange regarding Resignation of Mr. Rodolfo Hrosz as Non- Executive Director of the company w.e.f. February 28, 2026.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India's Board met on February 25, 2026 and approved audited financial results for the year ended December 31, 2025. Revenue from operations stood at Rs. 18,374 million (down from Rs. 20,132 million in FY24), while profit for the year was Rs. 3,267 million versus Rs. 4,135 million (the prior year included discontinued Consumer Healthcare operations). The Board recommended a final dividend of Rs. 48 per share, taking total FY25 dividend to Rs. 123 per share (including the interim Rs. 75). Mr. Rodolfo Hrosz resigned as Non-Executive Director effective February 28, 2026, citing other pre-occupations. The Board appointed Mrs. Rajani Kesari as Independent Director (5-year term from April 1, 2026) and Ms. Sudipta Chakraborty as Whole-time Director and Key Managerial Personnel (3-year term from March 1, 2026). Statutory auditors Price Waterhouse issued an unmodified opinion.
Revenue declined year-on-year, partly due to lower export sales after the end of the Zentiva contract, but core profitability and dividend payouts remained strong. The board reshuffle brings in experienced professionals (former CFO of Nayara Energy and a senior legal leader from Aditya Birla Group), which should reassure shareholders on governance continuity.